145 related articles for article (PubMed ID: 9007762)
1. Education and self-management of interferon beta-1b therapy for multiple sclerosis.
Keating MM; Ostby PL
J Neurosci Nurs; 1996 Dec; 28(6):350-2, 357-8. PubMed ID: 9007762
[TBL] [Abstract][Full Text] [Related]
2. An open-labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis.
Logan-Clubb L; Stacy M
J Neurosci Nurs; 1995 Dec; 27(6):344-7. PubMed ID: 8770778
[TBL] [Abstract][Full Text] [Related]
3. Factors leading patients to discontinue multiple sclerosis therapies.
Daugherty KK; Butler JS; Mattingly M; Ryan M
J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
[TBL] [Abstract][Full Text] [Related]
4. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
Gottesman MH; Friedman-Urevich S
Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
[TBL] [Abstract][Full Text] [Related]
5. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
6. [Formation of neutralizing antibodies in therapy of multiple sclerosis with interferon beta-1b. Practical procedure in suspected therapeutic failure].
Walther EU; Dang T; Hartung HP; Hohlfeld R
Nervenarzt; 1997 Dec; 68(12):935-9. PubMed ID: 9465334
[TBL] [Abstract][Full Text] [Related]
7. Nursing management of MS patients receiving interferon beta-1b therapy.
Costello K; Conway K
Rehabil Nurs; 1997; 22(2):62-6, 81. PubMed ID: 9110845
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects].
Walther EU; Dietrich E; Hohlfeld R
Nervenarzt; 1996 Jun; 67(6):452-6. PubMed ID: 8767199
[TBL] [Abstract][Full Text] [Related]
9. [PRISMS Study. Interferon-beta 1a (Rebif) in relapsing multiple sclerosis].
Hartung HP; Flachenecker P; Weilbach FX; Rieckmann P
Nervenarzt; 1999 Feb; 70(2):182-5. PubMed ID: 10098156
[No Abstract] [Full Text] [Related]
10. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis.
Schwartz CE; Coulthard-Morris L; Cole B; Vollmer T
Arch Neurol; 1997 Dec; 54(12):1475-80. PubMed ID: 9400356
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis.
Webster GF; Knobler RL; Lublin FD; Kramer EM; Hochman LR
J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):365-7. PubMed ID: 8655728
[TBL] [Abstract][Full Text] [Related]
12. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.
Blake G; Murphy S
Neurology; 1997 Dec; 49(6):1747-8. PubMed ID: 9409387
[No Abstract] [Full Text] [Related]
13. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
14. Multiple sclerosis pathways: an innovative nursing role in disease management.
Madonna MG; Keating MM
J Neurosci Nurs; 1999 Dec; 31(6):332-5. PubMed ID: 10726241
[TBL] [Abstract][Full Text] [Related]
15. [Interferon therapy of multiple sclerosis].
Jensen D
Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
[TBL] [Abstract][Full Text] [Related]
16. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
Wong J; Gomes T; Mamdani M; Manno M; O'Connor PW
Can J Neurol Sci; 2011 May; 38(3):429-33. PubMed ID: 21515501
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.
Schwid SR; Goodman AD; Mattson DH
Arch Neurol; 1997 Sep; 54(9):1169-90. PubMed ID: 9311363
[TBL] [Abstract][Full Text] [Related]
18. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis.
Turner AP; Williams RM; Sloan AP; Haselkorn JK
Rehabil Psychol; 2009 Feb; 54(1):116-21. PubMed ID: 19618711
[TBL] [Abstract][Full Text] [Related]
19. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
Tremlett HL; Oger J
Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
[TBL] [Abstract][Full Text] [Related]
20. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.
Pöllmann W; Erasmus LP; Feneberg W; Then Bergh F; Straube A
Neurology; 2002 Aug; 59(4):636-9. PubMed ID: 12196668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
